In light of the observation that delayed tPA treatment could result in HT, which could also lead to mortality in stroke patients, we evaluated whether G-CSF treatment reduced the mortality associated with delayed tPA therapy in stroke animals. The gene discussed is CSF3; the disease is stroke disorder.